Alexion wins early U.S. approval for rare blood disorder drug [Reuters (UK)]
STEMLINE THERAPEUTICS (STML)
Last stemline therapeutics earnings: 3/13 04:45 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.stemline.com/investor-relations
Company Research
Source: Reuters
Alexion wins early U.S. approval for rare blood disorder drug | Reuters 3 Min Read (Reuters) - The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc’s rare blood disorder drug Ultomiris, an early backing that also solidifies the company’s dominant market position. The company’s flagship drug, Soliris, was the lone FDA-approved treatment for the blood disorder, paroxysmal nocturnal hemoglobinuria (PNH), and raked in $3.13 billion last year, accounting for nearly 89 percent of total revenue. Ultomiris sales are expected to reach $1.66 billion by 2022, according to IBES data from Refinitiv, and the trial showed that the drug had results similar to Soliris. Also, patients on Ultomiris need medication only every eight weeks, compared every two weeks for those on Soliris. “With its strong profile, including a longer half-life and less frequent dosing and what we see as a superior clinical data package, we think this early approval will hasten Alexion’s market
Show less
Read more
Impact Snapshot
Event Time:
STML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STML alerts
High impacting STEMLINE THERAPEUTICS news events
Weekly update
A roundup of the hottest topics